Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study

Pancreatic cancer is a highly malignant digestive system tumor with a very poor prognosis. In recent years, both the incidence and mortality rates of pancreatic cancer have shown a marked upward trend worldwide. Global cancer statistics from 2020 indicate that approximately 495,000 new cases of pancreatic cancer are diagnosed annually, with about 466,000 deaths attributed to this disease each year. Based on the anatomical relationship between the tumor and blood vessels, pancreatic cancer is classified into three types: resectable, borderline resectable, and unresectable. The onset of pancreat

Trial Details

NCT ID

NCT07542002

Phase

PHASE2

Sponsor

Ningbo Medical Center Lihuili Hospital

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Irinotecan liposome, 5-fluorouracil/leucovorin, and oxaliplatin, with or without adadelimab.

Locations (sample)

Ningbo, China|29.87819,121.54945

Key Eligibility Criteria

Patients must meet the following criteria to be eligible for enrollment in this study:
Age 18 to 75 years, regardless of gender;
Histologically or cytologically confirmed pancreatic cancer (arising from the pancreatic ductal epithelium), as assessed by a multidisciplinary tea…
Presence of at least one measurable lesion as a target lesion (according to RECIST v1.1 criteria);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →